Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Energy
- Branch
- Not reported
- Recipient company
- ZYMERON CORPORATION
- Proposal award date
- 2023-07-10
- Contract end date
- 2024-04-09
- UEI
- GAMMMRQ6QMN1
- Solicitation number
- DE-FOA-0002903
- Topic code
- C56-31a
Research abstract
Management of chronic wounds remains a clinical challenge, especially when the wounds are infected by either biofilms or antibiotic-resistant microbial pathogens. Low temperature plasma (LTP) technique has demonstrated its proof of concept as an effective, non-antibiotic approach for wound disinfection. So far, commercial medical LTP devices leverage the direct exposure of plasma plume to the wound tissue, which leads to an increased risk of irreversible tissue damage. Besides the safety concerns, high manufacturing expenses and low portability among many other disadvantages prevent the widespread clinical translations of the LTP technology. Zymeron proposes to develop ZymPlasTM, a convenient, portable, and highly effective low temperature plasma device for chronic wound disinfection and healing at the point of care. ZymPlas adopts innovative plasma chemistry, which allows effective wound disinfection without the direct exposure of wound tissue to plasma plume. Besides, the novel plasma generation system and the compact design allow cost-effective manufacturing and improved portability. In the Phase I period, Zymeron will design and construct a functioning ZymPlasTM prototype device and optimize the relevant plasma chemistry. Next, the wound disinfection efficacy of the prototype device will be evaluated in ex vivo wound biofilm models using both Gram-negative and Gram-positive strains. Finally, the prototype device will be tested in a well-established mouse chronic wound infection model to validate the efficacy of wound disinfection and healing. ZymPlas can address wound infection and biofilm issues and thus brings significant clinical benefits (e.g., decreasing the wound chronicity, restoring impaired healing, reducing regular care frequency, shortening wound closure time) and reduces the financial and medical burden. Moreover, ZymPlas is also ideal for other applications such as acute trauma treatment, burn treatment, and surgical disinfection. The portable device design, simple operation procedure, and disinfection efficiency could match numerous applications in wound healing and dermatology therapeutic areas.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
42 SBIR/STTR records share this UEI (2017–2024). Reported award amounts total $24,710,238. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Defense, Department of Health and Human Services, Department of Energy
Agency intelligence
Department of Energy
Back to SBIR/STTR Research Awards